Cargando…

STAT3 and STAT5 Activation in Solid Cancers

The Signal Transducer and Activator of Transcription (STAT)3 and 5 proteins are activated by many cytokine receptors to regulate specific gene expression and mitochondrial functions. Their role in cancer is largely context-dependent as they can both act as oncogenes and tumor suppressors. We review...

Descripción completa

Detalles Bibliográficos
Autores principales: Igelmann, Sebastian, Neubauer, Heidi A., Ferbeyre, Gerardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826753/
https://www.ncbi.nlm.nih.gov/pubmed/31557897
http://dx.doi.org/10.3390/cancers11101428
_version_ 1783465165307510784
author Igelmann, Sebastian
Neubauer, Heidi A.
Ferbeyre, Gerardo
author_facet Igelmann, Sebastian
Neubauer, Heidi A.
Ferbeyre, Gerardo
author_sort Igelmann, Sebastian
collection PubMed
description The Signal Transducer and Activator of Transcription (STAT)3 and 5 proteins are activated by many cytokine receptors to regulate specific gene expression and mitochondrial functions. Their role in cancer is largely context-dependent as they can both act as oncogenes and tumor suppressors. We review here the role of STAT3/5 activation in solid cancers and summarize their association with survival in cancer patients. The molecular mechanisms that underpin the oncogenic activity of STAT3/5 signaling include the regulation of genes that control cell cycle and cell death. However, recent advances also highlight the critical role of STAT3/5 target genes mediating inflammation and stemness. In addition, STAT3 mitochondrial functions are required for transformation. On the other hand, several tumor suppressor pathways act on or are activated by STAT3/5 signaling, including tyrosine phosphatases, the sumo ligase Protein Inhibitor of Activated STAT3 (PIAS3), the E3 ubiquitin ligase TATA Element Modulatory Factor/Androgen Receptor-Coactivator of 160 kDa (TMF/ARA160), the miRNAs miR-124 and miR-1181, the Protein of alternative reading frame 19 (p19ARF)/p53 pathway and the Suppressor of Cytokine Signaling 1 and 3 (SOCS1/3) proteins. Cancer mutations and epigenetic alterations may alter the balance between pro-oncogenic and tumor suppressor activities associated with STAT3/5 signaling, explaining their context-dependent association with tumor progression both in human cancers and animal models.
format Online
Article
Text
id pubmed-6826753
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-68267532019-11-18 STAT3 and STAT5 Activation in Solid Cancers Igelmann, Sebastian Neubauer, Heidi A. Ferbeyre, Gerardo Cancers (Basel) Review The Signal Transducer and Activator of Transcription (STAT)3 and 5 proteins are activated by many cytokine receptors to regulate specific gene expression and mitochondrial functions. Their role in cancer is largely context-dependent as they can both act as oncogenes and tumor suppressors. We review here the role of STAT3/5 activation in solid cancers and summarize their association with survival in cancer patients. The molecular mechanisms that underpin the oncogenic activity of STAT3/5 signaling include the regulation of genes that control cell cycle and cell death. However, recent advances also highlight the critical role of STAT3/5 target genes mediating inflammation and stemness. In addition, STAT3 mitochondrial functions are required for transformation. On the other hand, several tumor suppressor pathways act on or are activated by STAT3/5 signaling, including tyrosine phosphatases, the sumo ligase Protein Inhibitor of Activated STAT3 (PIAS3), the E3 ubiquitin ligase TATA Element Modulatory Factor/Androgen Receptor-Coactivator of 160 kDa (TMF/ARA160), the miRNAs miR-124 and miR-1181, the Protein of alternative reading frame 19 (p19ARF)/p53 pathway and the Suppressor of Cytokine Signaling 1 and 3 (SOCS1/3) proteins. Cancer mutations and epigenetic alterations may alter the balance between pro-oncogenic and tumor suppressor activities associated with STAT3/5 signaling, explaining their context-dependent association with tumor progression both in human cancers and animal models. MDPI 2019-09-25 /pmc/articles/PMC6826753/ /pubmed/31557897 http://dx.doi.org/10.3390/cancers11101428 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Igelmann, Sebastian
Neubauer, Heidi A.
Ferbeyre, Gerardo
STAT3 and STAT5 Activation in Solid Cancers
title STAT3 and STAT5 Activation in Solid Cancers
title_full STAT3 and STAT5 Activation in Solid Cancers
title_fullStr STAT3 and STAT5 Activation in Solid Cancers
title_full_unstemmed STAT3 and STAT5 Activation in Solid Cancers
title_short STAT3 and STAT5 Activation in Solid Cancers
title_sort stat3 and stat5 activation in solid cancers
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826753/
https://www.ncbi.nlm.nih.gov/pubmed/31557897
http://dx.doi.org/10.3390/cancers11101428
work_keys_str_mv AT igelmannsebastian stat3andstat5activationinsolidcancers
AT neubauerheidia stat3andstat5activationinsolidcancers
AT ferbeyregerardo stat3andstat5activationinsolidcancers